Pancreatic steatosis in humans: cause or marker of lipotoxicity?
Authors:
- Daniël H van RaalteDRDaniël H van Raalte
- Nynke J van der ZijlNZNynke J van der Zijl
- Michaela DiamantMDMichaela Diamant
- 1 July 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 13 (4) , 478-485
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by impaired insulin secretion. Chronically increased levels of plasma nonesterified fatty acids (NEFA) and triglyceride-rich lipoproteins impair beta-cell function, a process referred to as lipotoxicity. Furthermore, when NEFA supply exceeds metabolic capacity, lipids accumulate in nonadipose tissues, such as pancreatic islets, inducing organ dysfunction. The purpose of this review is to describe the mechanisms underlying lipotoxicity in vitro, to discuss the evidence for lipotoxicity in vivo and to address whether pancreatic lipid accumulation interferes with insulin secretion in humans. Although numerous in-vitro studies have shown that chronically elevated NEFA levels induce beta-cell dysfunction and apoptosis, studies in humans are less conclusive. It has been acknowledged that concurrent hyperglycaemia amplifies the adverse effects of elevated plasma NEFA levels on beta-cell function; therefore glucolipotoxicity should be the preferred term. Lipid accumulation in pancreatic islets impaired beta-cell secretory capacity in leptin-deficient rodents. In humans, recent studies employing noninvasive magnetic resonance-technology and computed tomography-technology, lipid accumulation in the pancreas was increased in individuals with impaired glucose metabolism and T2DM. However, there was no clear association with beta-cell dysfunction. To date, it is difficult to provide evidence that intraislet lipid accumulation truly exists in humans and that it is indeed causal to beta-cell dysfunction. Additional research is warranted to further detail the nature and role of pancreatic lipid content in humans, its consequence for the postulated processes pertinent to glucolipotoxicity and its contribution to the progressive nature of beta-cell dysfunction in prediabetes.Keywords
This publication has 64 references indexed in Scilit:
- Noninvasive Quantification of Pancreatic Fat in HumansThe Journal of Clinical Endocrinology & Metabolism, 2009
- Ectopic lipids and organ functionCurrent Opinion in Lipidology, 2009
- Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetesBiochemical Society Transactions, 2008
- Preservation of β-cell function by targeting β-cell massTrends in Pharmacological Sciences, 2008
- Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type‐2 diabetesClinical Anatomy, 2007
- β-Cell Failure in Diabetes and Preservation by Clinical TreatmentEndocrine Reviews, 2007
- Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?BMJ, 2006
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999
- A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDMDiabetologia, 1995
- Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships.Proceedings of the National Academy of Sciences, 1994